Table 1

Disease characteristics determination
Patient ID	Age <br> (years)	BMI <br> (kg/m^²)	With CT-scan	With MRI	With PET-scan	Histology
05	62	18.2	Peritoneal carcinosis	Peritoneal carcinosis	Peritoneal carcinosis	Ovarian adenocarcinoma
06	65	19.8			Supra-diaphragmatic adenopathy	Serous papillary adenocarcinoma/peritoneal carcinosis
11	63	32.7	Ovarian mass	Ovarian mass	Peritoneal carcinosis	Ovarian adenocarcinoma
12	72	28.2	Right ovarian mass		Diffuse peritoneal carcinosis	Ovarian adenocarcinoma/peritoneal carcinosis
17	70	21.5	Pelvic mass with ascites	Peritoneal carcinosis with ascites	Ovarian lesion with peritoneal carcinosis	Ovarian adenocarcinoma
19	69	17.7	Ascites	Endometrial cancer		Ovarian papillary carcinoma
21	76	27.1		Cystic mass with peritoneal carcinosis		Ovarian adenocarcinoma
22	69	27.7	Mass with peritoneal carcinosis	Bilateral ovarian lesion with ascites and peritoneal carcinosis	Pelvic evolution and peritoneal carcinosis	Ovarian carcinoma
23	58	23.4		Suspected mixed ovarian cysts	Ovarian cystic evolution with peritoneal carcinosis and doubts on hepatic damage	High grade serous ovarian adenocarcinoma with localized peritoneal carcinosis
24	66	19.5			Peritoneal carcinosis	Ovarian serous adenocarcinoma
52	62	21.3	Peritoneal carcinosis			Serous type adenocarcinoma
54	66	24.6	Peritoneal carcinosis with ascites and depot on the diaphragm			Serous invasive carcinoma
55	79	35.8	Multiple peritoneal nodules with ascites			Serous carcinoma
57	66	24.7	Left ovarian mass with ascites and left pleural effusion			Serous papillary ovarian carcinoma
59	74	35.2	Peritoneal carcinosis with epiploic lesion and lymph nodes disease			Adenocarcinoma poorly differentiated

Table 1: Clinical characteristics of the patients included in the study

BMI, body mass index; CT, Computed Tomography; MRI, Magnetic Resonance Imaging; PET, Positron Emission Tomography.

Table 3

Patient ID	Preoperative time	Post-therapeutic treatment time
05	413; A	15.6; N
06	963; A	15.1; N
11	533; A	29; N
12	77; A	9.41; N
17	2400; A	18.1; N
19	1103; A	117; A
21	19,900; A	2900; A
22	1180; A	27; N
23	205; A	46.7; A
24	444; A	ND
52	897; A	131; A
54	3340; A	150; A
55	>1800; A	651; A
57	2040; A	235; A
59	437.2; A	ND

a)

IU, International Units; A, abnormal; N, normal; ND, non-determined.

The preoperative condition corresponds to the time of hospital admission. The post-therapeutic treatment condition corresponds to the time following chemotherapy and surgery.

Table 4

Patient ID	PCI <br>categorization	PCI <br>interpretation
05	TB	Favourable
06	TA	Favourable
11	TA	Favourable
12	TC	Favourable
12	TC	Favourable
17	TB	Favourable
19	TC	Favourable
21	TD	Unfavourable
22	TA	Favourable
23	TD	Unfavourable
24	TC	Favourable
52	TB	Favourable
54	TD	Unfavourable
55	TD	Unfavourable
57	TC	Favourable
59	TA	Favourable

b)

PCI, Peritoneal Cancer Index.

Table 6

Sample ID	% <br>Cytotoxicity (control)	% <br>Cytotoxicity (Carbo/Taxol)	Carbo/Taxol ratio	Oncogramme® categorization
05	6.8	33.3	4.879	S
06	11.6	45.7	3.945	S
11	8.3	11.1	1.340	I
12	19.4	16.7	0.862	R
12	47.9	36.3	0.758	R
17	15.4	40.9	2.665	I
19	3	9.6	3.266	I
21	7.4	10.9	1.463	I
22	6.3	18	2.843	I
23	7.6	19.8	2.613	I
24	7.4	21.1	2.858	I
52	13.9	29.9	2.161	I
54	1.7	7.5	4.470	S
55	13.1	15	1.147	R
57	3.8	3.7	0.968	R
59	8	29.4	3.686	S

a)

S, sensitive; R, resistant; I, intermediate.

Cells were treated with Carbo/Taxol [Carboplatin (50 µg/mL) and Paclitaxel (7 µg/mL)]. Carbo/Taxol ratios were calculated as follows: % Cytotoxicity Carbo/Taxol / % Cytotoxicity Control.

The Oncogramme® results were categorized according to percentile: R = resistant < 25th percentile < I = intermediate < 75^th percentile < S = sensitive.

Table 7

	Median	Minimum	Maximum	25^{^th} quartile	75^{^th} quartile
Carbo/Taxol ratio	2.639	0.758	4.897	1.291	3.371

b)

Table 8

PCI interpretation	Favourable<br>12/16	Unfavourable<br>4/16
Oncogrammecategorization
Sensitive or Intermediate<br>12/16	9 (A)	3 (B)
Resistant<br>4/16	3 (C)	1 (D)

Table 4: Table matching PCI interpretation with the Oncogramme^® categorization

Sensitivity 75%; Specificity 25%; PPV 75%; NPV 25%; Predictive Capacity 63%.

Table 10

Patient ID	RECIST 1.1 criteria	RECIST classification
05	2	PR
06	3	CR
11	2	PR
12	2	PR
17	2	PR
19	2	PR
21	2	PR
22	2	PR
23	3	CR
24	2	PR
52	2	PR
54	2	PR
55	1	SD
57	1	SD
59	2	PR

a)

RECIST, Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

Table 11

RECIST criteria	Responder<br>16/16	Non-responder<br>0/16
Oncogrammecategorization
Sensitive or Intermediate<br>12/16	12 (A)	0 (B)
Resistant <br>4/16	4 (C)	0 (D)

b)

Sensitivity 75 %; PPV 100%; Predictive Capacity 75%; Specificity and NPV were undetermined because none patient was Non-responder according to RECIST criteria.

Table 13

Patient ID	Surgical intervention
05	Laparotomy
06	Laparotomy
11	Laparotomy
12	No; evaluative coelioscopy
17	Debulking
19	No; interval exploratory coelioscopy
21	No; exploratory coelioscopy
22	Laparotomy
23	Debulking
24	Debulking
52	Laparotomy
54	Laparotomy
55	N/A
57	Laparotomy
59	Laparotomy

a)

N/A, not applicable.

Table 14

Patient operability	Yes<br>11/16	No<br>5/16
Oncogrammecategorization
Sensitive or Intermediate <br>12/16	10 (A)	2 (B)
Resistant <br>4/16	1 (C)	3 (D)

b)

Sensitivity 91%; Specificity 60%; PPV 83%; NPV 75%; Predictive Capacity 81%.

Tables at a glance

Table 1

Table 2

Table 3

Table 4

Table 5

Table 6

Table 7

Table 8

Table 9

Table 10

Table 11

Table 12

Table 13

Table 14

Figures at a glance

Comments

Figure 1

FIGURE 1

Figure 1: Flow chart showing the patient selection process